Patrick Dreyer, DO
Medical Oncology · Edina, MNNPI 1497127054
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.9% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,182 and has fallen 97.8% since, to $26 in 2025.
Across 111 payments — averaging $24.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$552
- Incyte Corporation$346
- Pfizer$262
- Merck$214
- AstraZeneca$146
- Dova Pharmaceuticals$125
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,51294%
- Education$1636%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 17 | $552 |
| Incyte Corporation | 12 | $346 |
| Pfizer | 11 | $262 |
| Merck | 13 | $214 |
| AstraZeneca | 9 | $146 |
| Dova Pharmaceuticals | 1 | $125 |
| Novartis | 7 | $108 |
| Gilead | 1 | $106 |
| Johnson & Johnson | 6 | $97 |
| Eisai Inc. | 5 | $91 |
| Rigel Pharmaceuticals, Inc. | 2 | $87 |
| Astellas Pharma US Inc | 3 | $56 |
| GSK | 3 | $56 |
| AbbVie | 3 | $55 |
| Beigene USA, Inc. | 1 | $50 |
| Seagen Inc. | 2 | $40 |
| Sanofi | 2 | $40 |
| Exelixis Inc. | 2 | $38 |
| Advanced Accelerator Applications | 2 | $35 |
| Foundation Medicine, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Novocure Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Genentech USA, Inc. | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Bayer | 1 | $13 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,675 in reported general payments places this provider in the 55th percentile of 133 medical oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 50 | $776,177 |
| OjjaaraMomelotinib Dihydrochloride | 16 | $404,653 |
| TagrissoOsimertinib Mesylate | 25 | $396,529 |
| CabometyxCabozantinib S-Malate | 15 | $374,564 |
| CalquenceAcalabrutinib Maleate | 14 | $205,853 |
| BrukinsaZanubrutinib | 16 | $125,507 |
| Lenalidomide | 13 | $113,077 |
| XareltoRivaroxaban | 28 | $39,742 |
| EliquisApixaban | 46 | $33,436 |
| Abiraterone Acetate | 35 | $13,519 |
| Exemestane | 33 | $9,141 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 16 | $3,772 |
| Anastrozole | 110 | $2,458 |
| Letrozole | 56 | $1,527 |
| Morphine Sulfate ErMorphine Sulfate | 30 | $1,212 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $552 | $776,17750 claims |
| AstraZenecaTagrisso, Calquence | $146 | $602,38339 claims |
| GSKOjjaara | $56 | $404,65316 claims |
| Exelixis Inc.Cabometyx | $38 | $374,56415 claims |
| Beigene USA, Inc.Brukinsa | $50 | $125,50716 claims |
| Johnson & JohnsonXarelto | $97 | $39,74228 claims |
| PfizerEliquis | $262 | $33,43646 claims |
| Lilly USA, LLCOlanzapine | $13 | $41147 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 133 medical oncology providers in Minnesota.
Other medical oncology in Edina
- Amy KrieMinneapolis$907K
- Amit MahipalRochester$746K
- Alton SartorRochester$688K
- Ben GeorgeRochester$579K
- Noel LaudiCoon Rapids$274K
- Emmanuel AntonarakisMinneapolis$260K
- Elisabeth HeathRochester$236K
- Matthew GoetzRochester$136K
- Charles RyanMinneapolis$99K
- Dean GesmeMinneapolis$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.